Multiple Myeloma

Gilead's $7.8B Arcellx Acquisition: Anito-Cel Deal Anatomy

Anatomy of Gilead's $7.8B acquisition of Arcellx for anito-cel, its December 2026 PDUFA date, iMMagine-1 trial data, and competition...